BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 26, 2026
Home » Shanghai Institute of Materia Medica

Articles Tagged with ''Shanghai Institute of Materia Medica''

Liver over digital lens background
Gastrointestinal

New PTP1B inhibitor ameliorates liver fibrosis in mice

Aug. 13, 2024
Liver fibrosis still lacks effective therapy; hepatic stellate cells (HSCs) are the primary fibrogenic cell type activated during liver injury. To date, almost half of the drugs used for liver treatment are natural product derivatives.
Read More
Endocrine/metabolic

Shanghai Institute of Materia Medica identifies new GLP-1R agonists

Aug. 9, 2024
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and obesity, among others.
Read More
Cancer

The Shanghai Institute of Materia Medica describes new ERRα inverse agonists

July 29, 2024
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered estrogen-related receptor α (ERRα; ERR1) inverse agonists reported to be useful for the treatment of cancer, obesity, hypertension, gallstone, osteoporosis, metabolic syndrome, hyperuricemia and Alzheimer's disease.
Read More
Neurology/psychiatric

Chinese scientists patent new NMDA receptor antagonists

June 6, 2024
Scientists at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and The Xinjiang Technical Institute of Physics & Chemistry of the Chinese Academy of Sciences have disclosed NMDA receptor antagonists reported to be useful for the treatment of neurological disorders.
Read More
Infection

3CLpro inhibitors for COVID-19 described in Chinese patent

May 31, 2024
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and the Wuhan Institute of Virology at the Chinese Academy of Sciences have divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More
Cardiovascular

Shanghai Institute of Materia Medica patents new compounds to treat arterial aneurysm

April 19, 2024
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed compounds reported to be useful for the treatment of arterial aneurysm.
Read More
Cancer

Discovery of potent MALT1 inhibitors with synergetic antitumor effects in models of B-cell lymphoma

March 12, 2024
Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and affiliated organizations published preclinical data for a new class of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors being developed as candidates for the treatment of lymphoma.
Read More
Cancer

Discovery of novel AXL inhibitor with potent antitumor activity in vivo

Feb. 19, 2024
Synthesis and optimization of a series of 1,6-naphthyridin-4-one derivatives led to the identification of the potent AXL inhibitor.
Read More
Cancer

Discovery of a potent METTL3-METTL14 complex PROTAC degrader with antileukemic potential

Feb. 5, 2024
The m6A methyltransferase complex is the main catalyzer of N6-methyladenosine (m6A) methylation, the most prevalent RNA modification.
Read More
Blister beetle on a flower
Cancer

Blistering agent derivative exerts anticancer activity

Jan. 19, 2024
Cantharidin, a natural product coming from blister beetles, has anti-proliferative activity in several cancer cell lines such as leukemia, myeloma or colon cancer cells.
Read More
Previous 1 2 3 4 5 6 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 24, 2026.
  • Boy cupping ear with soundwave graphic

    A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

    BioWorld
    Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
  • Illustration of a tumor

    Detecting the invisible: minimal residual disease at AACR 2026

    BioWorld Science
    Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
  • Illustration of human face that looks abstract and digital

    AACR 2026: The age of agentic AI in oncology

    BioWorld Science
    New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
  • In the clinic for April 21, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing